|Abacavir sulfate||Nucleoside analogue reverse transcriptase inhibitor|
|Lamivudine||Nucleoside analogue reverse transcriptase inhibitor|
|Zidovudine||Nucleoside analogue reverse transcriptase inhibitor|
|AHFS/Drugs.com||Professional Drug Facts|
|(what is this?)|
Abacavir/lamivudine/zidovudine, sold under the brand name Trizivir, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It contains three reverse transcriptase inhibitors patented by GlaxoSmithKline and marketed by a joint venture with Pfizer, ViiV Healthcare:
The most common effects include headache and nausea (feeling sick).
Abacavir/lamivudine/zidovudine was approved for use in the United States and the European Union in 2000. In December 2013, Lupin Limited launched a generic version of abacavir/lamivudine/zidovudine.
The most common side effects of abacavir/lamivudine/zidovudine include nausea, vomiting, diarrhea, fatigue, paresthesia and headache. As with many medications targeting reverse transcriptase, body fat redistribution syndrome may occur, causing body fat to center on the upper back and neck, breast, and torso, and potentially decreasing around the legs, arms, and face. IRIS may occur which is when the immune system initially improves, but then deteriorates as a previously ignored infection becomes active. Other serious side effects include:
- Increased risk of heart attack
- Lactic acidosis
- Severe hepatomegaly
- Hypersensitivity reactions
- "Abacavir / lamivudine / zidovudine (Trizivir) Use During Pregnancy". Drugs.com. 8 May 2018. Retrieved 7 April 2020.
- "Trizivir- abacavir sulfate, lamivudine, and zidovudine tablet, film coated". DailyMed. 10 May 2019. Retrieved 7 April 2020.
- "Trizivir EPAR". European Medicines Agency (EMA). Retrieved 7 April 2020.
- Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, et al. (May 2002). "A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection". The Journal of Infectious Diseases. 185 (9): 1251–60. doi:10.1086/340312. PMID 12001042.
- "GlaxoSmithKline-Pfizer launch HIV joint venture". InPharm.com. Archived from the original on 4 January 2012.
- Horvath T, Madi BC, Iuppa IM, Kennedy GE, Rutherford G, Read JS (January 2009). "Interventions for preventing late postnatal mother-to-child transmission of HIV". The Cochrane Database of Systematic Reviews (1): CD006734. doi:10.1002/14651858.CD006734.pub2. PMC 7389566. PMID 19160297.
- "Drug Approval Package: Trizivir (abacavir sulfate, lamivudine, zidovudine) NDA #021205". U.S. Food and Drug Administration (FDA). 28 March 2004. Retrieved 7 April 2020.
- Monthly Prescribing Reference (MPR)
- "Abacavir Sulfate". Lupin Pharma.
- "Abacavir sulfate, lamivudine and zidovudine: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 6 July 2020.
- ViiV Healthcare (March 2017). "Trizivir Medication Guide" (PDF). Archived (PDF) from the original on 22 December 2019.
- "Side Effects of Trizivir (Abacavir Sulfate, Lamivudine, and Zidovudine), Warnings, Uses". RxList. Retrieved 22 December 2019.
- "Abacavir sulfate mixture with lamivudine and zidovudine". Drug Information Portal. U.S. National Library of Medicine.